Physician

Craig Michael Alpert, MD

According to 2025 Medicare claims, Craig Alpert, MD (NPI: 1811215577) practices advanced heart failure and transplant cardiology in the Pittsburgh, PA market, with the plurality of this provider's patient population coming from Allegheny, PA. This provider's primary affiliated billing organization is ALLEGHENY CLINIC (NPI: 1104826734; TIN: 251838458) and primary practice location at 15212-4756. Alpert is affiliated with the Physician Partners of Western PA LLC (ACO ID: A3547), participating under the MSSP model.

Alpert's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 130 traditional Medicare patients, billed 402 HCPCS/CPT codes, and received $35,893 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 3,220 prescription claims across 270 beneficiaries totaling $9,269,084 in drug costs, led by Vyndamax (Tafamidis). DME data shows 61 claims. Open Payments data shows 5 records totaling $16,989. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,485 to $9,269,084. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	80	287	$21,574
2018	203	836	$73,542
2019	206	716	$68,459
2020	153	535	$49,626
2021	156	442	$50,588
2022	151	512	$53,070
2023	152	529	$58,011
2024	130	402	$35,893

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	14	36	$1,485
2016	21	59	$7,050
2017	98	283	$13,071
2018	300	2,477	$614,552
2019	367	3,816	$1,387,543
2020	406	4,080	$2,491,996
2021	379	4,231	$2,779,772
2022	308	3,689	$2,892,183
2023	258	3,133	$3,097,414
2024	270	3,220	$9,269,084

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	50	190	$16,522
2019	43	237	$17,999
2020	24	213	$29,716
2021	24	244	$21,535
2022	N/R	188	$27,260
2023	N/R	144	$17,260
2024	N/R	61	$1,114

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	23	23	$136
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	57	89	$124
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	28	63	$93
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	19	19	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	50	63	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	281	8,972	$6,676,773
Vyndaqel	Tafamidis Meglumine	40	1,200	$906,232
Winrevair	Sotatercept-Csrk	20	420	$450,534
Uptravi	Selexipag	13	390	$298,481
Adempas	Riociguat	12	360	$166,737

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	21	$519
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	20	$345
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$251

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$81	ABIOMED
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$16,908	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Craig Michael Alpert, MD?

Tedicare shows public-source Medicare data for Craig Michael Alpert, MD (NPI 1811215577), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Craig Michael Alpert, MD have ACO affiliation data?

Craig Michael Alpert, MD is shown with ACO affiliation data for Physician Partners of Western PA LLC (MSSP, ACO ID A3547).

What billing organization is linked to Craig Michael Alpert, MD?

Craig Michael Alpert, MD is linked to ALLEGHENY CLINIC (billing NPI 1104826734) in the available physician profile data.

Does Craig Michael Alpert, MD have Open Payments data?

Craig Michael Alpert, MD has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.